biomarin.com (BMRN) Quarterly EPS earnings growth

Symbol and logo of brand BioMarin Corp (BMRN)

Cost controls and Voxzogo sales are stabilizing the finances of BioMarin Pharmaceutical (BMRN), which the GURU.Markets system translates into quarterly EPS growth, where -294.90 is the current value of the indicator. AI gene expression models are enhancing efficiency by eliminating routine tasks for scientists. Further optimization is provided by robotic biosynthesis complexes that precisely dose enzymes, eliminating contamination in production zones.

BMRN: BioMarin Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/15/2026

BioMarin Pharmaceutical (BMRN) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:BioMarin Pharmaceutical
Flagship merchandise of BioMarin Corp

The specific nature of BioMarin Pharmaceutical (BMRN) business within the ultra-rare disease segment is directly reflected in the quarterly growth dynamics of earnings per share (EPS). This indicator measures the percentage change in net income per share relative to the same period last year. The calculation allows for an assessment of the monetization efficiency of unique drugs and the actual speed of business scaling. In an environment lacking competition and characterized by pricing power, this chart confirms the company's ability to convert its monopoly position into stable financial results. The long-term trend of this metric serves as an objective filter against market noise.

Who BioMarin Pharmaceutical competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BBIO (BridgeBio)|BGM: Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months Cogent Biosciences, Inc. COGT|XERS (Xeris Biopharma Inc) - Year-over-year net earnings per share trend for the last twelve months|Keros Therapeutics - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months ARCT (Arcturus Therapeutics)|ETON: Quarterly EPS earnings growth|Kamada Ltd (KMDA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Fulcrum Tx|ABEO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Mereo BioPharma Group (MREO)|Quarterly EPS earnings growth protalix.com (PLX)|Quarterly EPS earnings growth PLRX (Pliant Therapeutics Inc)|Quarterly EPS earnings growth Applied Therapeutics APLT|RNTX - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Year-over-year net earnings per share growth for the last 12 months|Chemomab Therapeutics Ltd - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth